Literature DB >> 21388709

Dynamic association of tau with neuronal membranes is regulated by phosphorylation.

Amy M Pooler1, Alessia Usardi, Catherine J Evans, Karen L Philpott, Wendy Noble, Diane P Hanger.   

Abstract

Tau is an abundant cytosolic protein which regulates cytoskeletal stability by associating with microtubules in a phosphorylation-dependent manner. We have found a significant proportion of tau is located in the membrane fraction of rat cortical neurons and is dephosphorylated, at least at Tau-1 (Ser199/Ser202), AT8 (Ser199/Ser202/Thr205) and PHF-1 (Ser396/Ser404) epitopes. Inhibition of tau kinases casein kinase 1 (CK1) or glycogen synthase kinase-3 decreased tau phosphorylation and significantly increased amounts of tau in the membrane fraction. Mutation of serine/threonine residues to glutamate to mimic phosphorylation in the N-terminal, but not C-terminal, region of tau prevented its membrane localization in transfected cells, demonstrating that the phosphorylation state of tau directly impacts its localization. Inhibiting CK1 in neurons lacking the tyrosine kinase fyn also induced tau dephosphorylation but did not affect its membrane association. Furthermore, inhibition of CK1 increased binding of neuronal tau to the fyn-SH3 domain. We conclude that trafficking of tau between the cytosol and the neuronal membrane is dynamically regulated by tau phosphorylation through a mechanism dependent on fyn expression.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21388709     DOI: 10.1016/j.neurobiolaging.2011.01.005

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  62 in total

Review 1.  Cellular factors modulating the mechanism of tau protein aggregation.

Authors:  Sarah N Fontaine; Jonathan J Sabbagh; Jeremy Baker; Carlos R Martinez-Licha; April Darling; Chad A Dickey
Journal:  Cell Mol Life Sci       Date:  2015-02-11       Impact factor: 9.261

Review 2.  The complexity of tau in Alzheimer's disease.

Authors:  Nima N Naseri; Hong Wang; Jennifer Guo; Manu Sharma; Wenjie Luo
Journal:  Neurosci Lett       Date:  2019-04-25       Impact factor: 3.046

3.  Development of dual casein kinase 1δ/1ε (CK1δ/ε) inhibitors for treatment of breast cancer.

Authors:  Andrii Monastyrskyi; Napon Nilchan; Victor Quereda; Yoshihiko Noguchi; Claudia Ruiz; Wayne Grant; Michael Cameron; Derek Duckett; William Roush
Journal:  Bioorg Med Chem       Date:  2017-12-15       Impact factor: 3.641

4.  C-Reactive Protein Induces Tau Hyperphosphorylation via GSK3β Signaling Pathway in SH-SY5Y Cells.

Authors:  Haibiao Guo; Haitao Wang; Canmao Wang; Yufang Cheng; Zhengqiang Zou; Yiwen Li; Jingang Wu; Jiangping Xu
Journal:  J Mol Neurosci       Date:  2015-05-13       Impact factor: 3.444

5.  An unbiased approach to identifying tau kinases that phosphorylate tau at sites associated with Alzheimer disease.

Authors:  Annalisa Cavallini; Suzanne Brewerton; Amanda Bell; Samantha Sargent; Sarah Glover; Clare Hardy; Roger Moore; John Calley; Devaki Ramachandran; Michael Poidinger; Eric Karran; Peter Davies; Michael Hutton; Philip Szekeres; Suchira Bose
Journal:  J Biol Chem       Date:  2013-06-24       Impact factor: 5.157

6.  Structural transitions in tau k18 on micelle binding suggest a hierarchy in the efficacy of individual microtubule-binding repeats in filament nucleation.

Authors:  Patrick Barré; David Eliezer
Journal:  Protein Sci       Date:  2013-06-24       Impact factor: 6.725

Review 7.  It's all about tau.

Authors:  Cheril Tapia-Rojas; Fabian Cabezas-Opazo; Carol A Deaton; Erick H Vergara; Gail V W Johnson; Rodrigo A Quintanilla
Journal:  Prog Neurobiol       Date:  2018-12-31       Impact factor: 11.685

8.  β-amyloid impairs the regulation of N-methyl-D-aspartate receptors by glycogen synthase kinase 3.

Authors:  Yulei Deng; Zhe Xiong; Paul Chen; Jing Wei; Shengdi Chen; Zhen Yan
Journal:  Neurobiol Aging       Date:  2013-10-01       Impact factor: 4.673

Review 9.  Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.

Authors:  Elvira Valera; Brian Spencer; Eliezer Masliah
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

10.  Tau Mislocation in Glucocorticoid-Triggered Hippocampal Pathology.

Authors:  Sara Pinheiro; Joana Silva; Cristina Mota; João Vaz-Silva; Ana Veloso; Vítor Pinto; Nuno Sousa; João Cerqueira; Ioannis Sotiropoulos
Journal:  Mol Neurobiol       Date:  2015-09-02       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.